March 29 (Reuters) - Eli Lilly will sign a $2 billion deal with Hong Kong-listed biotech Insilico Medicine, which usesartificial intelligencefor drug discovery, the Financial Times reported on Sunday.
Lilly will acquire exclusive rights to sell a GLP-1 drug for diabetes from Insilico Medicine, the FT report said, citing sources familiar with the matter.
Advertisement
Reuters could not immediately verify the report.
(Reporting by Rishabh Jaiswal in Bengaluru. Editing by Mark Potter)
